Skip to main content

Table 3 Multivariable analysis of prognostic factors for III-IVb NPC patients

From: Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein–Barr virus DNA level

 

Hazard ratio* (95% CI)

P value

Progression-free survival

 Age (y) (≥ 45 vs. <  45)

1.543(1.100–2.164)

0.012

 Gender(F vs. M)

1.055(0.814–1.366)

0.686

 T category (3–4 vs. 1–2)

1.280(0.846–1.937)

0. 242

 N category (2–3 vs. 0–1)

1.357(0.977–1.886)

0.069

 Overall stage (IVa-b vs. III)

1.487(1.133–1.951)

0.004

 EBV DNA

1.579(1.151–2.164)

0.005

 IC regimen; PF vs. TPF

1.189(0.880–1.605)

0.260

 IC regimen; TP vs. TPF

1.630(1.151–2.308)

0.006

Overall survival

 Age (y) (≥ 45 vs. <  45)

0.892(0.510–1.560)

0.688

 Gender(F vs. M)

1.846(1.115–3.055)

0.017

 T category (3–4 vs. 1–2)

0.967(0.475–2.177)

0.927

 N category (2–3 vs. 0–1)

1.161(0.620–2.177)

0.641

 Overall stage (IVa-b vs. III)

1.606(0.950–2.715)

0.077

 EBV DNA

3.881(1.657–9.090)

0.002

 IC regimen; PF vs. TPF

1.604(0.917–2.804)

0.098

 IC regimen; TP vs. TPF

1.571(0.719–3.436)

0.258

Locoregional relapse-free survival

 Age (y) (≥ 45 vs. <  45)

1.525(0.872–2.668)

0.139

 Gender(F vs. M)

0.970(0.631–1.492)

0.891

 T category (3–4 vs. 1–2)

1.189(0.598–2.364)

0.622

 N category (2–3 vs. 0–1)

0.890(0.542–1.462)

0.645

 Overall stage (IVa-b vs. III)

1.240(0.798–1.928)

0.339

 EBV DNA

1.672(0.983–2.843)

0.058

 IC regimen; PF vs. TPF

1.157(0.709–1.887)

0.559

 IC regimen; TP vs. TPF

1.298(0.711–2.369)

0.395

Distant metastasis-free survival

 Age (y) (≥ 45 vs. <  45)

1.592(1.051–2.411)

0.028

 Gender(F vs. M)

0.951(0.694–1.303)

0.756

 T category (3–4 vs. 1–2)

1.428(0.852–2.393)

0.177

 N category (2–3 vs. 0–1)

1.706(1.118–2.606)

0.013

 Overall stage (IVa-b vs. III)

1.488(1.071–2.068)

0.018

 EBV DNA

1.424(0.980–2.069)

0.063

 IC regimen; PF vs. TPF

1.349(0.940–1.936)

0.104

 IC regimen; TP vs. TPF

1.692(1.115–2.569)

0.013

  1. A Cox proportional hazards regression model was used to detect variables individually without adjustment. All variables were transformed into categorical variables. HRs were calculated for age (years) (≥45 vs. < 45), sex (female vs. male), T stage (T3–4 vs. T1–2), N stage (N2–3 vs. N0–1), plasma EBV DNA before the first treatment (≥1500 copies/ml vs. < 1500 copies/ml), overall stage (IVa-b vs. III), and IC regimen (PF vs. TPF, TP vs. TPF)
  2. Abbreviations: CI Confidence interval, EBV Epstein–Barr virus, IC Induction chemotherapy, TPF Taxanes plus cisplatin with fluorouracil, PF Cisplatin with fluorouracil, TP Taxanes with cisplatin
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us